jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Ankle tissue - Large Biopsy 3-6 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Large biopsy sample from ankle swelling/mass.

₹666₹951

30% OFF

Ankle Tissue - Large Biopsy 3-6 cm

  • Why is it done?
    • This test involves obtaining a tissue sample from the ankle region measuring 3-6 cm, which is a larger biopsy specimen used for comprehensive histopathological examination and diagnosis
    • To diagnose skin cancers or malignant melanomas affecting the ankle region
    • To evaluate suspicious lesions, nodules, or ulcers that require extensive tissue analysis
    • To assess infectious conditions including fungal, bacterial, or parasitic infections of ankle tissues
    • To investigate inflammatory or autoimmune conditions affecting the ankle
    • To evaluate vasculitis, connective tissue disorders, or dermatological conditions with systemic involvement
    • Typically performed when smaller punch or shave biopsies are insufficient for comprehensive diagnosis or when tumor margins require assessment
  • Normal Range
    • Normal results indicate the absence of malignant cells or pathogenic organisms; tissue architecture shows normal epidermal, dermal, and subcutaneous structures appropriate for ankle location
    • No specific numerical values apply; results are reported qualitatively as either NEGATIVE or POSITIVE for pathology
    • NEGATIVE Result: Normal benign tissue without malignancy, significant inflammation, or infectious organisms
    • POSITIVE Result: Presence of malignant cells, specific diagnosis of disease, infection, or significant pathology requiring treatment
    • Results provided with detailed descriptive pathology report rather than quantitative measurements
  • Interpretation
    • Malignant Findings:
    • Melanoma - diagnosis confirmed with Breslow depth assessment, Clark level, mitotic rate, and presence of ulceration important for staging and prognosis
    • Squamous cell carcinoma - requires assessment of differentiation grade and depth of invasion
    • Basal cell carcinoma - evaluated for subtypes and whether margins are adequately clear
    • Infectious Findings:
    • Fungal infections - identification of causative organisms guides antifungal therapy selection
    • Bacterial or tuberculous infections - specific organisms identified allowing targeted antibiotic treatment
    • Parasitic infections - organism identification determines appropriate antiparasitic therapy
    • Inflammatory and Autoimmune Findings:
    • Vasculitis - specific type identified (leukocytoclastic, granulomatous) guides systemic workup and treatment
    • Lupus erythematosus - interface dermatitis and fibrinoid necrosis may be present suggesting systemic involvement
    • Sarcoidosis - noncaseating granulomas help distinguish from other granulomatous conditions
    • Factors Affecting Interpretation:
    • Sample fixation and processing quality affects diagnostic accuracy
    • Adequate tissue margins crucial for determining if lesion completely removed
    • Specimen orientation and depth assessment important for accurate tumor staging
    • Clinical correlation with patient history enhances diagnostic interpretation
  • Associated Organs
    • Primary Organ Systems:
    • Integumentary system (skin) - primary tissue being evaluated
    • Lymphatic system - affected in cases of melanoma or other malignancies with lymphatic involvement
    • Vascular system - involved in vasculitis or vascular malformations
    • Diseases Diagnosed or Monitored:
    • Cutaneous melanoma - with risk of metastasis to regional lymph nodes and distant organs
    • Non-melanoma skin cancers (squamous cell and basal cell carcinomas)
    • Dermatophyte infections and other fungal infections
    • Systemic lupus erythematosus with cutaneous manifestations
    • Vasculitis disorders (polyarteritis nodosa, granulomatosis with polyangiitis)
    • Mycobacterial infections (tuberculosis, atypical mycobacterial infections)
    • Sarcoidosis with skin involvement (erythema nodosum, lupus pernio)
    • Cutaneous manifestations of systemic diseases
    • Potential Complications of Abnormal Results:
    • Melanoma diagnosis requires staging including sentinel lymph node biopsy and imaging to assess for metastatic disease
    • Positive margin findings may necessitate re-excision for complete tumor removal
    • Systemic disease identification requires comprehensive workup and specialist consultation
    • Infectious findings require treatment and may indicate disseminated disease in immunocompromised patients
  • Follow-up Tests
    • If Melanoma Diagnosed:
    • Sentinel lymph node biopsy - to assess lymph node involvement and stage disease
    • CT chest, abdomen, and pelvis or PET-CT imaging - to evaluate for distant metastases
    • Brain MRI - for high-risk melanomas to screen for cerebral metastases
    • Genetic testing (BRAF, c-KIT mutations) - to guide immunotherapy or targeted therapy options
    • Baseline metabolic panel and LDH - for prognostic information
    • If Non-Melanoma Skin Cancer Confirmed:
    • Re-excision if margins are positive or inadequate
    • Dermatology follow-up for surveillance and monitoring
    • Regular skin surveillance examinations for recurrence or new lesions
    • If Infection Identified:
    • Culture and sensitivity testing - to identify specific organisms and guide antibiotic/antifungal selection
    • Gram stain and special stains (acid-fast, fungal stains) - for organism identification
    • PCR testing - for specific organisms (mycobacteria, fungi) if indicated
    • Systemic workup if disseminated infection suspected (chest X-ray, additional imaging)
    • If Systemic/Inflammatory Disease Found:
    • Autoimmune serology (ANA, anti-dsDNA, ESR, CRP) - to evaluate for systemic lupus or other connective tissue disorders
    • Chest X-ray and ACE level - if sarcoidosis suspected
    • ANCA and complement levels - if vasculitis suspected
    • Rheumatology or infectious disease consultation as indicated
    • Monitoring Schedule:
    • Melanoma Stage I: Clinical surveillance every 3-6 months for 3 years, then annually
    • Melanoma Stage II-III: Closer follow-up with physical exams and imaging as recommended by oncology
    • Infectious diseases: Follow-up after treatment completion to ensure cure
  • Fasting Required?
    • NO - Fasting is NOT required for this tissue biopsy procedure
    • Patient Preparation Instructions:
    • Wear loose, comfortable clothing with easy access to the ankle
    • Cleanse the biopsy site with soap and water the night before and morning of procedure
    • Do NOT apply lotions, creams, makeup, or sunscreen to the ankle area on day of biopsy
    • Avoid aspirin and NSAIDs for 5-7 days before procedure if possible (increases bleeding risk) - consult physician if on these medications
    • Continue taking all other regular medications unless specifically instructed otherwise by the physician
    • If on anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban) notify physician prior to procedure
    • Arrange for transportation as local or regional anesthesia will be used and may cause mild drowsiness
    • Post-Procedure Care:
    • Keep biopsy site clean and dry with sterile dressing for 24-48 hours
    • Apply antibiotic ointment if prescribed
    • Avoid strenuous activities and exercise for 3-7 days
    • Avoid immersing wound in water for at least 24 hours
    • Monitor for signs of infection: increased pain, redness, warmth, drainage, or fever

How our test process works!

customers
customers